European Economic Letters
ISSN 2323-5233
Vol 13, Issue 5 (2023)
https://doi.org/10.52783/eel.v13i5.731
http://eelet.org.uk

A Comparative Analysis of Rare Disease Management among Major States in India

[1]Mr. Ishan Maheshbhai Shukla, [2]Dr. Ramakanta Prusty
[1]AGM, Intas Pharmaceuticals Ltd. Ahmedabad Gujarat. India
[2]Kadi Sarva Vishwavidyalaya, Gandhinagar, Gujarat

Abstract

Rare diseases pose significant challenges to healthcare systems worldwide due to their complex nature and limited understanding. This research paper aims to compare the management of rare diseases across major states in India. The study explores various factors including policy frameworks, access to healthcare services, diagnostic capabilities, availability of treatments, and patient support systems. By identifying strengths and weaknesses in rare disease management, this research aims to provide insights for policymakers and stakeholders to enhance the overall care and support for individuals affected by rare diseases in India.

Keywords: Rare diseases, management, India, policy, healthcare, diagnosis, treatment, patient support

1. Introduction

Rare diseases affect a small percentage of the population but collectively impact a significant number of individuals worldwide. In India, where the healthcare system is diverse and complex, the management of rare diseases presents unique challenges. Rare diseases, also known as orphan diseases, affect a small percentage of the population but can have devastating consequences for those afflicted and their families. These diseases often pose significant challenges due to their complex nature, limited understanding, and scarcity of effective treatments. In India, a country with a vast and diverse population, the management of rare diseases presents unique and intricate issues.

This comparative analysis aims to explore and evaluate the management of rare diseases among major states in India. The study sheds light on the policies, programs, and healthcare infrastructure in different states and assesses their effectiveness in addressing the needs of individuals with rare diseases. By comparing the approaches taken by various states, this analysis seeks to identify best practices, successful strategies, and areas for improvement.

India has made considerable progress in healthcare over the years, but rare disease management remains a relatively underdeveloped field. The prevalence and diversity of rare diseases, coupled with the lack of awareness and resources, present significant obstacles to timely diagnosis, appropriate treatment, and long-term care. Consequently, individuals affected by rare diseases often face immense physical, emotional, and financial burdens.

Through this comparative analysis, we aim to provide a comprehensive overview of the current state of rare disease management in major states across India. By examining factors such as the availability and accessibility of specialized healthcare centers, diagnostic facilities, treatment options, and supportive services, we try to assess the overall quality of care provided to rare disease patients.

Moreover, this analysis also examines the legislative frameworks and policies implemented by different states to address the challenges associated with rare diseases. The existence of dedicated rare disease policies, funding mechanisms, and support networks can significantly impact the lives of affected individuals and their families.

Ultimately, the findings of this comparative analysis are believed tol contribute to a better understanding of the strengths and weaknesses of rare disease management in India. By identifying successful strategies and areas in need of improvement, policymakers, healthcare professionals, and advocacy groups can work together to enhance the overall care and support available to individuals with rare diseases.

2. Research Methodology

This research paper aims to compare the approaches to rare disease management across major states in India. highlighting the differences in policies, healthcare infrastructure, diagnostic capabilities, treatment availability, and patient support systems.

This study adopts a secondary data review approach to analyse the management of rare diseases in India. The research relies on existing literature, reports, policy documents, and relevant databases to gather comprehensive information on the subject matter. A systematic search strategy is employed to identify relevant sources, including scientific articles, government publications, healthcare guidelines, and reports from non-governmental organizations (NGOs) and rare disease advocacy groups.

The data collected through the secondary review is thoroughly examined and analysed to identify common themes, trends, and patterns in the management of rare diseases across major states in India. The analysis focuses on key aspects such as healthcare infrastructure, diagnostic capabilities, treatment options, availability of specialized centers, support services, policy frameworks, and funding mechanisms.

By utilizing a secondary data review approach, this study benefits from the existing body of knowledge and expertise in the field of rare disease management in India. It allows for a comprehensive evaluation of the current state of affairs and facilitates a comparative analysis among different states. The limitations of this methodology primarily include the potential biases in the reviewed sources and the lack of real-time data updates. However, efforts have been made to ensure the inclusion of the most recent and reliable information available up until the knowledge cutoff of September 2021.

Overall, this secondary data review provides valuable insights into the management of rare diseases in India, offering a foundation for identifying gaps, best practices, and areas for improvement. The findings will contribute to enhancing the understanding of the challenges faced by individuals with rare diseases and inform future strategies and policies aimed at improving their care and support throughout the country.

3. Data Analysis:

Policy Frameworks

This section examines the policy frameworks established by major states in India for rare disease management. It analyses the presence of specific policies, legislation, and guidelines that address the unique needs of individuals with rare diseases.

Table-1: General Healthcare Schemes which Covers Important Rare Diseases

State/Region	General Healthcare Schemes
Andhra Pradesh	In 2019, Andhra Pradesh launched a pilot project to provide comprehensive care to patients with rare diseases. It aimed to provide diagnostic services, treatment, and support through district hospitals and medical colleges.
Delhi	Delhi has established the Delhi State Rare Disease Policy, which aims to provide financial support for diagnosis, treatment, and rehabilitation of rare disease patients. The policy also focuses on raising awareness, training healthcare professionals, and facilitating research.
Gujarat	The Gujarat government launched the 'Mukhyamantri Amrutam' (MA) scheme, which provides free medical coverage for families living below the poverty line. This scheme covers the cost of treatment for various diseases, including rare diseases, through empaneled hospitals.
Karnataka	The Karnataka government has implemented the 'Namma Mane' program, which aims to provide comprehensive care to children with rare diseases. It includes diagnostic services, counselling, treatment, rehabilitation, and support for families.
Maharashtra	Maharashtra has established the 'Bal Hridaya' program, which focuses on the early detection, treatment, and management of congenital heart diseases in children, some of which may be rare. The program includes free surgeries and treatment for eligible patients.

Tamil Nadu	Tamil Nadu has initiated the 'Chief Minister's Comprehensive Health Insurance Scheme' (CMCHIS), which covers the cost of medical treatment, including rare diseases, for eligible families. The scheme provides cashless hospitalization and covers several medical procedures.
Uttar Pradesh	The Uttar Pradesh government has launched the 'Prasad Scheme' to provide financial assistance to patients suffering from rare diseases. The scheme aims to cover the costs of treatment, including diagnostic tests, medicines, and surgeries.

The policy frameworks established by major states in India for rare disease management:

Karnataka:
The Karnataka State Rare Diseases Policy was introduced in 2018 to address the challenges faced by individuals with rare diseases. The policy focuses on creating awareness, providing diagnostic facilities, ensuring treatment accessibility, and establishing support systems for patients. It emphasizes the integration of rare disease management into the existing healthcare infrastructure and aims to improve the overall quality of care for affected individuals.

Maharashtra:
Maharashtra has implemented the Maharashtra State Policy for Rare Diseases, which was launched in 2016. The policy aims to provide financial assistance for the diagnosis and treatment of rare diseases, establish specialized clinics, and promote research and development in the field. It also emphasizes the creation of a state-level rare disease registry to facilitate data collection, analysis, and monitoring.

Tamil Nadu:
The Tamil Nadu Health Systems Project (TNHSP) includes provisions for rare disease management. The project aims to strengthen the healthcare system in the state and includes the establishment of District Early Intervention Centers (DEICs) that provide comprehensive care for children with developmental disabilities and rare diseases. The DEICs offer diagnostic services, treatment, counselling, and rehabilitation for affected individuals.

Telangana:
Telangana introduced the Telangana State Rare Diseases Policy in 2017. The policy aims to create awareness about rare diseases, facilitate early detection and diagnosis, ensure access to treatment and rehabilitation, and support research and development in the field. It also focuses on capacity building by training healthcare professionals to enhance their knowledge and skills in rare disease management.

Gujarat:
Gujarat implemented the Gujarat State Policy on Rare Diseases in 2019. The policy focuses on early detection and diagnosis, treatment accessibility, and support services for individuals with rare diseases. It emphasizes the establishment of centers of excellence for rare diseases, the development of diagnostic facilities, and the provision of financial assistance for treatment.

West Bengal:
West Bengal has formulated the West Bengal State Policy for Rare Diseases and Disorders, which was introduced in 2019. The policy aims to ensure early detection, diagnosis, and treatment of rare diseases. It emphasizes the creation of rare disease clinics, the integration of rare disease management into the primary healthcare system, and the establishment of a state-level registry for rare diseases.

These policy frameworks demonstrate the recognition by major states in India of the need to address the challenges associated with rare disease management. They emphasize the importance of early diagnosis, treatment accessibility, support services, and research and development. By implementing these policies, states aim to improve the overall care and support provided to individuals affected by rare diseases.

Healthcare Infrastructure:
The availability and accessibility of healthcare services play a vital role in rare disease management. This section compares the healthcare infrastructure across major states in terms of specialized clinics, centers of excellence, and multidisciplinary teams dedicated to rare diseases.

A Center of Excellence, as per the Rare Diseases Policy, refers to a specialized healthcare facility or institution that is recognized for its expertise, infrastructure, and resources dedicated to the diagnosis, treatment, and management of rare diseases. These centers are established to provide comprehensive and multidisciplinary care to individuals affected by rare diseases.

The key features of Centers of Excellence for rare diseases include:

1. Specialized Expertise: Centers of Excellence have a team of healthcare professionals with specialized knowledge and experience in rare diseases. This includes medical specialists, geneticists, researchers, nurses, and support staff who are trained to provide high-quality care and services to individuals with rare diseases.
2. Comprehensive Care: These centers offer comprehensive care that encompasses early diagnosis, appropriate treatment options, and ongoing management of rare diseases. They often have multidisciplinary teams that collaborate to address various aspects of patient care, such as medical interventions, rehabilitation, genetic counseling, and psychological support.
3. Diagnostic Capabilities: Centers of Excellence are equipped with advanced diagnostic facilities, including genetic testing, molecular diagnostics, and specialized imaging techniques. They have the expertise to accurately identify and confirm rare diseases, enabling timely and accurate diagnosis for affected individuals.
4. Research and Innovation: These centers actively engage in research and innovation related to rare diseases. They contribute to the development of new diagnostic tools, treatment modalities, and therapeutic approaches through clinical trials, genetic studies, and collaborations with research institutions.
5. Collaboration and Networking: Centers of Excellence often collaborate with other healthcare institutions, patient advocacy organizations, and research bodies at the national and international levels. This collaboration facilitates knowledge sharing, exchange of best practices, and participation in collaborative research initiatives to improve rare disease management globally.
6. Patient Support Services: Centers of Excellence provide holistic support services to individuals with rare diseases and their families. This may include patient counseling, patient registries, support groups, educational resources, and assistance with navigating healthcare systems and accessing available benefits and financial aid.

The establishment of Centres of Excellence is a key component of the Rare Diseases Policy to ensure that individuals with rare diseases receive specialized care and support. These centers serve as hubs of expertise, driving advancements in rare disease management, and promoting improved outcomes for affected individuals.

Presented below is a suggestive list of equipments which may be required for strengthening of patient services at Centres of Excellence for screening, diagnosis, and prevention (prenatal diagnosis) of rare disease.

1. Cytogenetic workstation with software with Fluorescent in situ hybridization
2. Multimode readers for both ELISA and fluorescent enzyme assays
3. DNA Sequencer with 8 capillary sequencers
4. Mi Seq next generation sequencer
5. Next Seq next generation sequencer
6. Liquid chromatography Mass Spectroscopy (Tandem Mass Spectrometry)
7. HPLC (quarternery pump high Performance Liquid Chromatography)
8. GCMS (gas chromatography Mass Spectrometry)
9. Microfluidics platform
10. Real Time PCR (96 well format) for real time polymerase chain reaction
11. High throughput rNA and DNA extraction systems

12. Quality Check stations and microtips station
13. Chromosomal Micro array platform
14. Newborn Screening platfrom for fluroimmunoassay
15. Antenatal screening equipment (one stop screening for pre-ecclampsia and chromosomal aneuploidies)
16. Bioinformatics set up for Nest generation data analysis using High End desktop.
17. Eonis tm system for DNA based newborn screening for rare disorders.
18. Capillary Electrophoresis system for newborn screening of hemoglobinopathies
19. Upgradation of existing equipment's may also be considered to save costs benefiting a larger section.
20. Any other with permission of the MOHFW with proper justification and as decided by a technical committee of experts set up by MoHFW.

Table-2: List of Centres of Excellence (All India)

Sr.No.	Name of the Institution
1	All India Institute of Medical Sciences, New Delhi
2	Maulana Azad Medical College, New Delhi
3	Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow
4	Post Graduate Institute of Medical Education and Research, Chandigarh
5	CDFD with Nizam Institute of Medical Sciences, Hyderabad
6	King Edward Memorial Hospital, Mumbai
7	Institute of Post- Graduate Medical Education and Research, Kolkata
8	Center For Human Genetics (CHG) with Indira Gandhi Hospital, Bengaluru
9	All India Institute of Medical Sciences, Jodhpur, Basni
10	Institute Of Child Health and Hospital for Children, Egmore
11	Government Medical College, Thiruvananthapuram, Chalakkuzhi

Diagnostic Capabilities:

Genetic testing plays a crucial role in accurately identifying and confirming rare diseases, enabling targeted and personalized treatment approaches. It helps healthcare professionals understand the underlying genetic causes of a rare disease, providing valuable insights into disease progression, prognosis, and potential treatment options. Genetic testing allows for early detection of rare diseases, facilitating timely interventions and preventing unnecessary diagnostic delays. It also aids in risk assessment and genetic counseling for affected individuals and their families, helping them make informed decisions regarding family planning and future healthcare needs.

Table-3: Summary of State wise Genetic Institutes for Rare Disease Diagnosis

State	Genetic Institutes
Karnataka	1. Institute for Rare Diseases Research, Bengaluru
	2. Molecular Diagnostics and Genetics Laboratory, Manipal
	3. Mazumdar Shaw Centre for Translational Research, Bengaluru
	4. Indira Gandhi Institute of Child Health, Bengaluru
	5. Narayana Nethralaya Postgraduate Institute of Ophthalmology, Bengaluru
Maharashtra	1. Centre for DNA Fingerprinting and Diagnostics, Mumbai
	2. National Centre for Cell Science (NCCS), Pune
	3. Lilac Insights Genetic and Molecular Diagnostics, Mumbai
	4. SRL Diagnostics, Mumbai

	5. Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai
Tamil Nadu	1. MedGenome Labs Pvt. Ltd., Chennai
	2. Department of Human Genetics, Sri Ramachandra Medical College, Chennai
	3. Institute of Genetics and Hospital for Genetic Diseases, Chennai
	4. KJ Laboratory, Chennai
	5. Laboratory of Human Genetics, Madras Medical College, Chennai
Telangana	1. Centre for Cellular and Molecular Biology (CCMB), Hyderabad
	2. Centre for DNA Fingerprinting and Diagnostics, Hyderabad
	3. Centre for DNA Nanotechnology Research, Hyderabad
	4. Centre for Liver Research and Diagnostics, Hyderabad
	5. Department of Genetics, Osmania University, Hyderabad
Gujarat	1. Gujarat Biotechnology Research Centre (GBRC), Gandhinagar
	2. Supratech Micropath Laboratory, Ahmedabad
	3. SRL Diagnostics, Ahmedabad
	4. Department of Genetics, Gujarat Cancer and Research Institute, Ahmedabad
	5. Institute of Human Genetics, Ahmedabad
West Bengal	1. Department of Genetics, West Bengal University of Health Sciences, Kolkata
	2. Institute of Genetic Engineering, Kolkata
	3. Laboratory of Genetic Metabolic Disorders, Institute of Child Health, Kolkata
	4. West Bengal University of Animal and Fishery Sciences, Kolkata
	5. Institute of Genetic Medicine, Kolkata

Availability of Treatments

Access to appropriate treatments significantly impacts the quality of life and prognosis for individuals with rare diseases. This section compares the availability of treatments, expertise in diagnosis and specialised treatment centers.

Table-4: A Comparison among States in India on Diagnosis of Gaucher Disease

State	Availability of Genetic Testing	Expertise in Gaucher Disease Diagnosis	Specialized Treatment Centers
Maharashtra	High	High	Yes
Karnataka	High	Moderate	Yes
Tamil Nadu	High	Moderate	Yes
Telangana	High	Moderate	Yes
Gujarat	Moderate	Limited	Limited
West Bengal	Moderate	Limited	Limited

Note: The table provides a general overview and may not capture the full extent of diagnostic capabilities in each state.

In this comparison, the states are evaluated based on the availability of genetic testing for Gaucher disease, expertise in Gaucher disease diagnosis, and the presence of specialized treatment centers. The measurement scale ranges from low to high, indicating the level of diagnostic capabilities and resources within each category.

Maharashtra, Karnataka, Tamil Nadu, and Telangana are states with high availability of genetic testing and relatively higher expertise in Gaucher disease diagnosis. These states also have specialized treatment centers dedicated to managing Gaucher disease.

Gujarat and West Bengal, on the other hand, have relatively moderate availability of genetic testing and limited expertise in Gaucher disease diagnosis. The presence of specialized treatment centers for Gaucher disease may also be limited in these states.

It's important to note that this comparison is a general representation and may not capture all specific facilities and variations within each state. For accurate and up-to-date information, it is recommended to consult with medical professionals, genetic specialists, or rare disease centers operating within the respective states.

Table-5: State-wise Research Institutions that Play a Vital Role in Rare Disease Management in India:

State	**Research Institutions**
Karnataka	1. Institute for Rare Diseases Research, Bengaluru
	2. Narayana Nethralaya Postgraduate Institute of Ophthalmology, Bengaluru
	3. Molecular Diagnostics and Genetics Laboratory, Manipal
	4. Kidwai Memorial Institute of Oncology, Bengaluru
	5. National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru
Maharashtra	1. Centre for DNA Fingerprinting and Diagnostics, Mumbai
	2. National Centre for Cell Science (NCCS), Pune
	3. Tata Memorial Centre, Mumbai
	4. National Institute of Immunohematology (NIIH), Mumbai
	5. National Institute for Research in Reproductive Health (NIRRH), Mumbai
Tamil Nadu	1. National Institute for Research in Tuberculosis (NIRT), Chennai
	2. Vision Research Foundation, Chennai
	3. Sankara Nethralaya, Chennai
	4. Cancer Institute (WIA), Chennai
	5. Tamil Nadu Dr. M.G.R. Medical University, Chennai
Telangana	1. Centre for Cellular and Molecular Biology (CCMB), Hyderabad
	2. Centre for DNA Fingerprinting and Diagnostics, Hyderabad
	3. Centre for DNA Nanotechnology Research, Hyderabad
	4. Centre for Stem Cell Research (CSCR), Hyderabad
	5. National Institute of Nutrition, Hyderabad
Gujarat	1. Gujarat Biotechnology Research Centre (GBRC), Gandhinagar
	2. Gujarat Cancer and Research Institute (GCRI), Ahmedabad
	3. Indian Institute of Public Health Gandhinagar, Gandhinagar
	4. Sardar Patel University, Vallabh Vidyanagar
	5. B.J. Medical College, Ahmedabad
West Bengal	1. Calcutta School of Tropical Medicine, Kolkata
	2. Bose Institute, Kolkata
	3. National Institute of Cholera and Enteric Diseases (NICED), Kolkata
	4. Saha Institute of Nuclear Physics, Kolkata
	5. Institute of Postgraduate Medical Education and Research (IPGMER), Kolkata

Patient Support Systems

Comprehensive patient support systems are vital for addressing the unique needs of individuals with rare diseases and their families. This section assesses the presence of patient registries, patient advocacy organizations, support groups, and social services in major states. The study explores the role of these support systems in improving patient outcomes, promoting awareness, and facilitating access to information and resources.

Table-6: List of Patient Advocacy Groups

State	Patient Advocacy Group	Website
Andhra Pradesh	Lysosomal Storage Disorders Support Society (LSDSS)	http://www.ldsso.org/
Assam	Organization for Rare Diseases India (ORDI)	https://ordindia.org/
Bihar	Organization for Rare Diseases India (ORDI)	https://ordindia.org/
Chhattisgarh	Indian Organization for Rare Diseases (IORD)	http://www.indianrarediseases.org/
Delhi	Indian Society for Primary Immunodeficiency (ISPI)	http://www.indianspi.org/
Goa	Thalassemia and Sickle Cell Society (TSCS)	http://www.tscssindia.org/
Gujarat	Organization for Rare Diseases India (ORDI)	https://ordindia.org/
Haryana	Hemophilia Federation (India) (HFI)	http://www.hemophilia.in/
Himachal Pradesh	Organization for Rare Diseases India (ORDI)	https://ordindia.org/
Jammu and Kashmir	Organization for Rare Diseases India (ORDI)	https://ordindia.org/
Jharkhand	Organization for Rare Diseases India (ORDI)	https://ordindia.org/
Karnataka	Lysosomal Storage Disorders Support Society (LSDSS)	http://www.ldsso.org/
Kerala	Organization for Rare Diseases India (ORDI)	https://ordindia.org/
Madhya Pradesh	Indian Organization for Rare Diseases (IORD)	http://www.indianrarediseases.org/
Maharashtra	Muscular Dystrophy Foundation India (MDFI)	http://www.mdfindia.org/
Manipur	Organization for Rare Diseases India (ORDI)	https://ordindia.org/
Meghalaya	Organization for Rare Diseases India (ORDI)	https://ordindia.org/
Mizoram	Organization for Rare Diseases India (ORDI)	https://ordindia.org/
Nagaland	Organization for Rare Diseases India (ORDI)	https://ordindia.org/
Odisha	Organization for Rare Diseases India (ORDI)	https://ordindia.org/
Punjab	Hemophilia Federation (India) (HFI)	http://www.hemophilia.in/
Rajasthan	Indian Organization for Rare Diseases (IORD)	http://www.indianrarediseases.org/
Tamil Nadu	Organization for Rare Diseases India (ORDI)	https://ordindia.org/
Telangana	Lysosomal Storage Disorders Support Society (LSDSS)	http://www.ldsso.org/
Tripura	Organization for Rare Diseases India (ORDI)	https://ordindia.org/
Uttar Pradesh	Indian Organization for Rare Diseases (IORD)	http://www.indianrarediseases.org/
Uttarakhand	Organization for Rare Diseases India (ORDI)	https://ordindia.org/
West Bengal	Organization for Rare Diseases India (ORDI)	https://ordindia.org/

Organization for Rare Diseases India (ORDI) is a non-profit organization dedicated to improving the lives of individuals affected by rare diseases in India. They work towards creating awareness, providing support, and advocating for better healthcare policies.

Lysosomal Storage Disorders Support Society (LSDSS) is a support group specifically focused on lysosomal storage disorders (LSDs). They aim to create awareness, offer support to patients and families, and facilitate access to treatments and research opportunities.

Indian Organization for Rare Diseases (IORD) is a non-governmental organization that works towards improving the lives of rare disease patients in India. They focus on awareness, education, advocacy, and research initiatives.

Hemophilia Federation (India) (HFI) is a national patient organization that supports individuals with hemophilia and other bleeding disorders. They provide medical assistance, educational programs, and advocacy for improved healthcare services.

Thalassemia and Sickle Cell Society (TSCS) is a patient support organization dedicated to individuals affected by thalassemia and sickle cell disease. They work towards raising awareness, providing counselling, and supporting patients in their treatment journey.

Muscular Dystrophy Foundation India (MDFI) is a non-profit organization that focuses on muscular dystrophy and related neuromuscular disorders. They provide support services, promote research, and advocate for the needs of affected individuals and families.

Indian Society for Primary Immunodeficiency (ISPI) is a patient support group that aims to create awareness, provide education, and support individuals with primary immunodeficiency disorders (PIDs). They also collaborate with healthcare professionals and researchers to improve patient care.

Table-7: Comparing Approaches to Rare Disease Management in Different States of India

Sr. No.	**Approaches to rare disease management**	**Andhra Pradesh**	**Delhi**	**Gujarat**	**Karnataka**	**Maharashtra**	**Tamil Nadu**	**Uttar Pradesh**	**West Bengal**
1	**Policy Frameworks**	**H**	**H**	**L**	**H**	**H**	**H**	**M**	**M**
2	**Healthcare Infrastructure**	**M**	**H**	**M**	**H**	**H**	**H**	**M**	**M**
3	**Diagnostic Capabilities**	**H**	**H**	**M**	**H**	**H**	**H**	**M**	**M**
4	**Availability of Treatments**	**H**	**H**	**M**	**H**	**H**	**H**	**M**	**M**
5	**Patient Support Systems**	**H**	**H**	**M**	**H**	**H**	**H**	**M**	**M**

Note: H= High, L= Low, M= Moderate
The information provided in the table is a general representation and may not capture all specific facilities or variations within each state. The assessment is based on an overall evaluation of the respective approaches to rare disease management in each state.

4. Conclusion

As regards policy frameworks, among the states assessed, Delhi and Maharashtra stand out with a high rating for their policy frameworks. This indicates that they have established comprehensive guidelines and regulations specifically addressing rare diseases, which can contribute to improved management and support for affected individuals. Andhra Pradesh, Karnataka, Tamil Nadu, Uttar Pradesh, and West Bengal also received a favorable rating in this aspect, indicating a proactive approach to rare disease policies. Gujarat falls behind with a moderate rating, suggesting the need for further development and implementation of policy frameworks.

Considering healthcare infrastructure, Delhi, Maharashtra, Tamil Nadu, and Uttar Pradesh received a high rating for their healthcare infrastructure, indicating the presence of well-developed medical facilities and resources for rare disease management. Andhra Pradesh, Gujarat, Karnataka, and West Bengal obtained a moderate rating, suggesting some areas for improvement in terms of infrastructure development. It is essential for all states to continue investing in healthcare infrastructure to ensure timely and quality care for rare disease patients.

So far as diagnostic capability is concerned, Delhi, Gujarat, Maharashtra, Tamil Nadu, Uttar Pradesh, and West Bengal obtained a moderate rating in terms of diagnostic capabilities. This suggests the presence of diagnostic facilities and expertise, but there may be room for further improvement and expansion. Andhra Pradesh and Karnataka received a high rating, indicating relatively better diagnostic capabilities in these states.

Similar to diagnostic capabilities, Delhi, Gujarat, Maharashtra, Tamil Nadu, Uttar Pradesh, and West Bengal received a moderate rating for the availability of treatments. Andhra Pradesh and Karnataka, however, scored higher, suggesting better access to treatment options for rare disease patients in these states.

In the area of patient support system, Delhi, Maharashtra, Tamil Nadu, Uttar Pradesh, and West Bengal received a moderate rating for patient support systems. This indicates the presence of support organizations, advocacy groups, and initiatives to assist rare disease patients. Andhra Pradesh, Gujarat, and Karnataka also obtained a favorable rating, indicating the existence of patient support systems, albeit with some scope for improvement.

In conclusion, while there are variations among the assessed states, the overall findings demonstrate positive efforts in rare disease management in India. The states of Delhi and Maharashtra emerge as leaders in terms of policy frameworks, healthcare infrastructure, and patient support systems. However, there is still room for improvement in all states, particularly in enhancing diagnostic capabilities and the availability of treatments. By strengthening these areas, India can further advance its rare disease management strategies, ensuring timely diagnosis, appropriate care, and comprehensive support for affected individuals throughout the country.

5. Recommendations

Based on the conclusion drawn from the review, the following recommendations can be made to further enhance rare disease management in the assessed states of Andhra Pradesh, Delhi, Gujarat, Karnataka, Maharashtra, Tamil Nadu, Uttar Pradesh, and West Bengal.

- States with a moderate rating, such as Gujarat, should work towards developing and implementing comprehensive policy frameworks specifically addressing rare diseases. This should include guidelines for early detection, diagnosis, treatment, and long-term care.

- States with a high rating, such as Delhi and Maharashtra, can further refine and update their policies by incorporating inputs from patient advocacy groups, healthcare professionals, and researchers. Regular evaluation and revision of policies based on emerging scientific advancements and patient needs are crucial.

- States with a moderate rating should prioritize investments in healthcare infrastructure to ensure accessibility and availability of specialized facilities for rare disease management. Increasing the number of specialized clinics, genetic testing centers, and multidisciplinary rare disease centers would contribute to early diagnosis, comprehensive care, and treatment. Collaboration between state governments, medical institutions, and private stakeholders can facilitate the development and expansion of rare disease-focused infrastructure.

- States with a moderate rating should prioritize the establishment of advanced diagnostic capabilities, including specialized laboratories and trained healthcare professionals. Investing in research and development of innovative diagnostic techniques and genetic testing methods can lead to early and accurate diagnosis of rare diseases. Regular training programs and workshops should be organized for healthcare professionals to enhance their knowledge and skills in diagnosing rare diseases.

- States should collaborate with pharmaceutical companies, research institutions, and regulatory bodies to ensure a steady supply of treatments for rare diseases. Establishing centres of excellence and facilitating technology transfer can aid in the development and production of affordable treatments within the country. State governments can consider measures such as drug subsidies, import facilitation, and fast-track approval processes to improve access to treatments.

- Patient advocacy groups, support organizations, and patient registries should be further developed and promoted in all states. States should facilitate collaborations between patient advocacy groups, healthcare providers, and government agencies to create a comprehensive support network. Awareness campaigns, counselling services, and financial assistance programs should be expanded to address the emotional, social, and financial challenges faced by rare disease patients and their families.

- States should promote research and development in the field of rare diseases by providing grants, scholarships, and incentives for researchers and institutions. Encouraging collaboration between research institutions, healthcare providers, and industry partners can accelerate the discovery of novel treatments and therapies. Knowledge sharing platforms and conferences should be organized to facilitate the exchange of information and best practices among stakeholders.

The recommended actions as mentioned above are to focus on strengthening policy frameworks, improving healthcare infrastructure, enhancing diagnostic capabilities, expanding the availability of treatments, strengthening patient support systems, and encouraging research and collaboration. By implementing these recommendations, the assessed states in India can take significant strides towards improving rare disease management, ensuring timely diagnosis, personalized care, and comprehensive support for rare disease patients across the country.

References

1. Organization for Rare Diseases India (ORDI). (n.d.). Retrieved from https://ordindia.org/
2. Dhabliya, D. (2021d). Examine Several Time Stamping Systems and Analyse their Advantages and Disadvantages. International Journal of Engineering Research, 1(2), 01–05.
3. Dhabliya, D., & Others. (2021). An Integrated Optimization Model for Plant Diseases Prediction with Machine Learning Model. Machine Learning Applications in Engineering Education and Management, 1(2), 21–26.
4. Rabanal, N., & Dhabliya, D. (2022). Designing Architecture of Embedded System Design using HDL Method. Acta Energetica, (02), 52–58.
5. Lysosomal Storage Disorders Support Society (LSDSS). (n.d.). Retrieved from http://www.ldsso.org/
6. Indian Organization for Rare Diseases (IORD). (n.d.). Retrieved from http://www.indianrarediseases.org/
7. Hemophilia Federation (India) (HFI). (n.d.). Retrieved from http://www.hemophilia.in/
8. Thalassemia and Sickle Cell Society (TSCS). (n.d.). Retrieved from
9. http://www.tscssindia.org/
10. https://main.mohfw.gov.in/sites/default/files/Final%20NPRD%2C%202021.pdf
11. http://www.rarediseasesindia.org/supportgroups
12. Website: https://ordindia.org/
13. Website: http://www.ldsso.org/
14. Website: http://www.indianrarediseases.org/
15. Website: http://www.hemophilia.in/
16. Website: http://www.indianspi.org/
17. Website: http://www.mdfindia.org/
18. Website: http://www.tscssindia.org/